Shares of Indivior PLC (NASDAQ:INDV – Get Free Report) have received an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $22.00.
INDV has been the subject of several research reports. Jefferies Financial Group initiated coverage on Indivior in a research note on Tuesday, July 22nd. They issued a “buy” rating and a $20.00 target price for the company. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Indivior in a research note on Wednesday. Wall Street Zen upgraded Indivior from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 21st. Finally, HC Wainwright began coverage on Indivior in a research note on Wednesday, August 6th. They set a “buy” rating and a $27.00 price target for the company.
Check Out Our Latest Stock Analysis on Indivior
Hedge Funds Weigh In On Indivior
Indivior Price Performance
Shares of INDV opened at $23.78 on Friday. The stock has a 50-day moving average of $23.51 and a 200-day moving average of $16.48. The company has a market cap of $3.28 billion, a PE ratio of 38.36 and a beta of 0.70. Indivior has a one year low of $7.33 and a one year high of $25.10.
Indivior (NASDAQ:INDV – Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.26 by $0.25. The company had revenue of $302.00 million during the quarter, compared to the consensus estimate of $239.43 million. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. Indivior has set its FY 2025 guidance at EPS. Analysts expect that Indivior will post 1.22 EPS for the current fiscal year.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Read More
- Five stocks we like better than Indivior
- What Makes a Stock a Good Dividend Stock?
- Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
- Retail Stocks Investing, Explained
- AST SpaceMobile’s Big Win: Shares Soar on New Deal With Verizon
- What is a penny stock? A comprehensive guide
- Catch the Next Bitcoin Rally With These 3 ETFs
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.